Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment USP

Manufacturer
Rebel Distributors Corp
Effective date
2011-01-03
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:11:07

Label at a glance#

ProductNeomycin and Polymyxin B Sulfates and Bacitracin Zinc
Active ingredientNeomycin Sulfate, Polymyxin B Sulfate, Bacitracin Zinc
Label structure12 sections

Indications and uses

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

Dosage and administration

Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

Storage and handling

Store between 15° - 30°C (59°- 86°F). KEEP OUT OF REACH OF CHILDREN. STERILE OPHTHALMIC OINTMENT Rx Only

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment USP is a sterile antimicrobial ointment for ophthalmic use.

Each Gram Contains:

ACTIVES: Neomycin Sulfate (equivalent to 3.5 mg neomycin base), Polymyxin B Sulfate equivalent to 10,000 polymyxin B units, and Bacitracin Zinc equivalent to 400 bacitracin units; INACTIVES: White Petrolatum, Mineral Oil.

Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 micrograms of neomycin standard per milligram, calculated on an anhydrous basis. The structural formulae are:

Neomycin Sulfate Chemical Structure
Neomycin Sulfate Chemical Structure

Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis.

The structural formulae are:

Polymyxin B Sulfate Chemical Structure
Polymyxin B Sulfate Chemical Structure

Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per milligram.

The structural formula for bacitracin A is:

Bacitracin Zinc Chemical Structure
Bacitracin Zinc Chemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin.

Neomycin is bactericidal for many gram-positive and gram-negative organisms. It is an aminoglycoside antibiotic which inhibits protein synthesis by binding with ribosomal RNA and causing misreading of the bacterial genetic code.

Polymyxin B is bactericidal for a variety of gram-negative organisms. It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.

Bacitracin is bactericidal for a variety of gram-positive and gram-negative organisms. It interferes with bacterial cell wall synthesis by inhibition of the regeneration of phospholipid receptors involved in peptidoglycan synthesis.

Microbiology: Neomycin sulfate, polymyxin B sulfate and bacitracin zinc together are considered active against the following microorganisms:

Staphylococcus aureus, streptococci including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is contraindicated in those individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE.

Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should never be directly introduced into the anterior chamber of the eye. Ophthalmic ointments may retard corneal wound healing.

Topical antibiotics, particularly neomycin sulfate, may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical antibiotics is not known. The manifestations of sensitization to topical antibiotics are usually itching, reddening, and edema of the conjunctiva and eyelid. A sensitization reaction may manifest simply as a failure to heal. During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. Symptoms usually subside quickly on withdrawing the medication. Application of products containing these ingredients should be avoided for the patient thereafter (see PRECAUTIONS: General).

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

As with other antibiotic preparations, prolonged use of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may result in overgrowth of nonsusceptible organisms including fungi. If superinfection occurs, appropriate measures should be initiated.

Bacterial resistance to neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment may also develop. If purulent discharge, inflammation, or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

There have been reports of bacterial keratitis associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom had a concurrent corneal disease or a disruption of the ocular epithelial surface (see PRECAUTIONS: Information for Patients).

Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.

Information for patients

INFORMATION FOR PATIENTS SECTION

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface.

The use of this product by more than one person may spread infection.

Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated products (see PRECAUTIONS: General).

If the condition persists or gets worse, or if a rash or allergic reaction develops, the patient should be advised to stop use and consult a physician. Do not use this product if you are allergic to any of the listed ingredients.

Keep tightly closed when not in use. Keep out of reach of children.

Carcinogenesis, mutagenesis, impairment of fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin. Treatment of cultured human lymphocytes in vitro with neomycin increased the frequency of chromosome aberrations at the highest concentration (80 mcg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.

Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown. No adverse effects on male or female fertility, litter size or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet.

Pregnancy

PREGNANCY SECTION

Teratogenic effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C. Animal reproduction studies have not been conducted with neomycin sulfate, polymyxin B sulfate, or bacitracin. It is also not known whether neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment should be given to a pregnant woman only if clearly needed.

Nursing mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment is administered to a nursing woman.

Pediatric use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions have occurred with the anti-infective components of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely.

Local irritation on instillation has also been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

HOW SUPPLIED

HOW SUPPLIED SECTION

Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment USP 21695-192-35 is supplied in a 3.5 g tube with an ophthalmic tip.

DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.

FOR OPHTHALMIC USE ONLY

STORAGE

STORAGE AND HANDLING SECTION

Store between 15° - 30°C (59°- 86°F).

KEEP OUT OF REACH OF CHILDREN.

STERILE OPHTHALMIC OINTMENT

Rx Only

MANUFACTURER INFORMATION

SPL UNCLASSIFIED SECTION

Bausch & Lomb Incorporated
Tampa, FL 33637
©Bausch & Lomb Incorporated

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Neomycin/ Poly B/Bac 3.5mg/10,000 Units/400 UnitsNeomycin/ Poly B/Bac 3.5mg/10,000 Units/400 Units

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
308493bacitracin zinc 400 UNT / neomycin sulfate 3.5 MG / polymyxin B sulfate 10,000 UNT per GM Ophthalmic OintmentPSN1
308493bacitracin 0.4 UNT/MG / neomycin 0.0035 MG/MG / polymyxin B 10 UNT/MG Ophthalmic OintmentSCD1
308493bacitracin 0.4 UNT/MG / neomycin 0.35 % / polymyxin B 10 UNT/MG Ophthalmic OintmentSY1
308493bacitracin 400 UNT / neomycin 3.5 MG / polymyxin B 10,000 UNT per GM Ophthalmic OintmentSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
BACITRACIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
NEOMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
POLYMYXIN B Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
99e684e6-f435-feb8-d2bb-3a546f1cb768Product name220161117
25340b3b-3e4c-4ff8-abf6-3e62ec46bd0cProduct name120160603
2d352c73-a357-4193-a4de-dfdf9a2ac8e4Product name120150819
b045ad64-0f28-9a02-2f9b-b34d94fb2278Product name120140508
b6082387-f592-1148-0844-bd068fd213fbProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
21695-192-352019-09-24C16284748780-1934fe258-4b09-48b1-e053-8cdaa90a720aNeomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment USP

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-192-35Neomycin and Polymyxin B Sulfates and Bacitracin Zinc3.5 g in 1 TUBEOINTMENT3.51

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-192NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC (NEOMYCIN SULFATE, POLYMYXIN B SULFATE AND BACITRACIN ZINC) OINTMENT [REBEL DISTRIBUTORS CORP]1Legacy NDC, 1 package rows20110113_65b71a14-dcb5-4123-b4c5-033c9e16a22a.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21695-192-35GM - Gram21695-192a29db007-702b-4d86-9ab7-63b5a0b8fabd12012-07-24
24208-780-55GM - Gram24208-78064224556-80ef-4dbc-8727-e3cc191b591812012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Bacitracin ZincACTIVE INGREDIENT89Y4M234ES1
Neomycin SulfateACTIVE INGREDIENT057Y6266931
Polymyxin B SulfateACTIVE INGREDIENT19371312D41
BacitracinACTIVE MOIETY58H6RWO52I1
NeomycinACTIVE MOIETYI16QD7X2971
polymyxin BACTIVE MOIETYJ2VZ07J96K1
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-19221695-192-35
24208-780

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 2 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / OPHTHALMIC88.4 %w/wExact identifier — unii+route+dosage form
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / OPHTHALMIC59.5 %w/wExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINCBACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064064-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3084e616aacf4f…
2026-08-18 06:07:402026-07A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-3087673890dc5c…
2021-03-12 10:30 UTC2021-03A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-303f01610625f2…
2019-09-15 20:21 UTC2019-09A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30b00525d2431f…
2019-07-19 19:46 UTC2019-07A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-303f0d92c62455…
2023-05-13 08:27 UTC2023-05A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30053a50430f4f…
2023-01-26 05:58 UTC2023-01A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-303bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-303a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064064-001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GMOINTMENT / OPHTHALMICATRS1995-10-30f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064064-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064064-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064064-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064064-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064064-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064064-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064064-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064064-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064064-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064064-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064064-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064064-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064064-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064064-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064064-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064064-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064064-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064064-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064064-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064064-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064064-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064064-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064064-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064064-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064064-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064064-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064064-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064064-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064064-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064064-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064064-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064064-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064064-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064064-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064064-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064064-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064064-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064064-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064064-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064064-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Neomycin and Polymyxin B Sulfates and Bacitracin ZincNEOMYCIN SULFATE, POLYMYXIN B SULFATE AND BACITRACIN ZINCBausch & Lomb Incorporatedf3231f1c-665e-4efa-baa1-83bf296b2f8f2025-01-02Warnings, Adverse reactionsExact identifier
ndc (product): 24208-780
65b71a14-dcb5-4123-b4c5-033c9e16a22a65b71a14-dcb5-4123-b4c5-033c9e16a22a2011-01-03Warnings, Adverse reactionsExact identifier
spl id: 65b71a14-dcb5-4123-b4c5-033c9e16a22a
spl set id: 65b71a14-dcb5-4123-b4c5-033c9e16a22a

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.